Status:
COMPLETED
Arimidex Therapy Compliance Electronic Monitoring System
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Aardex Pharmionic
Conditions:
Breast Cancer
Eligibility:
FEMALE
Brief Summary
ARTEMIS is a study to assess how educational material affects overall adherence to anastrozole by evaluation of patients' electronically compiled dosing histories. Patients' dosing times are compiled ...
Eligibility Criteria
Inclusion
- Postmenopausal women with hormone sensitive early breast cancer.
- Documented decision of treatment with anastrozole which will start in 13 weeks according to current SmPC OR current treatment with anastrozole according to current SmPC, that has not exceeded thirteen weeks before enrollment.
- Subjects who accept to use MEMS® monitors to automatically compile their drug dosing histories.
Exclusion
- Concomitant or previous use of adjuvant tamoxifen, letrozole or exemestane for the current tumour.
- Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff or staff at the study site).
- Participation in another clinical study with an investigational product during the last 3 months.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT00936442
Start Date
June 1 2009
End Date
December 1 2010
Last Update
February 14 2012
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Brussels, Belgium
2
Research Site
Leuven, Belgium
3
Research Site
Liège, Belgium
4
Research Site
Overpelt, Belgium